Skip to content
OpenCapital
Get started

Inhibrx Biosciences, Inc. INBX Business Segments — Research And Development Expense, Personnel

Similar metrics at other companies

Crinetics Pharmaceuticals logo
CRNXReportable Segment — Research And Development Personnel Expenses
$30.65M+19.6%
Biohaven logo
BHVNReportable Segment — R&D personnel expense (excluding share-based compensation)
$21.01M-0.6%
Bicara Therapeutics logo
BCAXReportable Segment — Research and development personnel cost and other (including stock-based compensation)
$9.12M+79.0%
Agios Pharmaceuticals logo
AGIOReportable Segment — R&D
$23.91M+12.1%
Agios Pharmaceuticals logo
AGIOReportable Segment — Research and Development Arrangement, Contract to Perform for Others, Compensation Earned
$36.79M+11.5%
Immunovant, Inc. logo
IMVTReportable Segment — R&D
$29.22M-6.2%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+546%
Enterprise value$1.42B+1,233%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept inhibrx:ResearchAndDevelopmentExpensePersonnel.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s business segments — research and development expense, personnel.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s business segments — research and development expense, personnel?
Inhibrx Biosciences, Inc. (INBX) reported business segments — research and development expense, personnel of $8.53M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s business segments — research and development expense, personnel changed year-over-year?
Inhibrx Biosciences, Inc.'s business segments — research and development expense, personnel decreased by 8.6% year-over-year, from $9.33M to $8.53M.
What does business segments — research and development expense, personnel mean?
This metric captures the compensation and benefits for staff directly involved in research and development activities. It reflects the human capital investment required to support scientific discovery and drug development programs. Monitoring this helps assess the scale and intensity of the company's internal R&D capabilities.